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Abstract
Background: In pairwise meta-analysis, the contribution of each study to the pooled estimate is given by its weight,
which is based on the inverse variance of the estimate from that study. For network meta-analysis (NMA), the
contribution of direct (and indirect) evidence is easily obtained from the diagonal elements of a hat matrix. It is,
however, not fully clear how to generalize this to the percentage contribution of each study to a NMA estimate.
Methods: We define the importance of each study for a NMA estimate by the reduction of the estimate’s variance
when adding the given study to the others. An equivalent interpretation is the relative loss in precision when the
study is left out. Importances are values between 0 and 1. An importance of 1 means that the study is an essential link
of the pathway in the network connecting one of the treatments with another.
Results: Importances can be defined for two-stage and one-stage NMA. These numbers in general do not add to
one and thus cannot be interpreted as ‘percentage contributions’. After briefly discussing other available approaches,
we question whether it is possible to obtain unique percentage contributions for NMA.
Conclusions: Importances generalize the concept of weights in pairwise meta-analysis in a natural way. Moreover,
they are uniquely defined, easily calculated, and have an intuitive interpretation. We give some real examples for
illustration.
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Background
Pairwise meta-analysis (pairwise MA) is used to summa-
rize the evidence for a treatment effect from all eligible
studies that compared the two interventions of interest.
In two-stage pairwise MA, the contribution of each study
to the pooled estimate is measured by its weight, which
depends on the type of data, the chosen summary mea-
sure, and the chosen statistical model. For example, for
mean differences usually the inverse of the variance of
the estimated mean difference for a study is used as that
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study’s weight, though this is an estimated, not a fixed
number.
Network meta-analysis (NMA) extends the pairwise
MA approach to an arbitrary number of interventions.
It is usually based on a set of randomized trials, each
comparing a subset of two or more of the treatments
that are of interest for the underlying research question.
The evidence from these studies is then put together in a
model, preferably respecting the principle of concurrent
control by using a model that is based on the within-study
treatment contrasts [1].
The objective is to describe how important each study
is for the estimate of a given treatment effect in the NMA.
We distinguish between approaches that focus on the
study’s contribution in the sense of attributing a ‘weight’
to each study, mainly depending on the variances, and
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approaches that also take into account the direction and
size of each treatment effect, and which are seeking for
‘influential’ or explicitly ‘outlying’ studies. For the lat-
ter, see [2–5]. In this paper, we concentrate on the first
approach; that is, we are mainly interested in measur-
ing study contributions without looking at their effect
estimates.
For NMA, while several methods exist to obtain the
contribution of direct (and indirect) evidence of each
comparison to its own NMA estimate, it is far less obvi-
ous how to define the contribution, or the importance, of
each study to any (other) treatment effect estimate. Sev-
eral proposals exist in the literature, based on different
approaches. Most of them come with some limitations;
their results also do not in general agree [6–9].
The proportions of direct and indirect evidence have
been investigated in the past. The method of ‘back-
calculation’, which we describe in the “Methods” section,
goes back to Bucher’s work [10] and was proposed by
Dias and others in a Bayesian framework [11]. It was also
given in a frequentist context [12]. In NMA based on
the inverse variance method, NMA estimates are linear
combinations of treatment effect estimates from primary
studies with coefficients that constitute the rows of the
hat matrix. The direct evidence proportion of a study or
a comparison is easily obtained from the diagonal ele-
ments of the respective hat matrix [12]. As an alternative,
Dias and others suggested ‘node splitting’, which means
estimating the indirect evidence for a comparison bymod-
eling out all studies that provide direct information for this
comparison [11]. This method was developed further [13]
and called ‘side splitting’ by others [14]. Whereas White
[14] interpreted the term ‘side’ as an edge in the network
graph, others used SIDE as an abbreviation of ‘Separating
Indirect and Direct Evidence’ [15, 16]. Noma and others
proposed quantifying the indirect evidence based on a fac-
torization of the total likelihood into separate component
likelihoods [17]. So far, these authors did not undertake
to define or estimate the contribution of each study to a
given comparison in the network.
A proposal to this aim, based on the off-diagonal ele-
ments of the hat matrix, was made by Salanti and others
[6]. Implicitly, this idea also underlies the net heat plot
that was suggested by Krahn and others, a heatmap visu-
alization representing the absolute size of the hat matrix
elements by gray squares [18]. However, as an approach
to define percentage study contributions, it has problems,
as the hat matrix elements are signed and do not add to
1. Papakonstantinou and others, acknowledging this lim-
itation, developed a different concept, likewise based on
the hat matrix, using ideas by König and others [12], and
successfully avoided these deficiencies [9]. Although the
proposed algorithm is not strictly deterministic, it was
empirically shown that this did not materially affect the
estimated percentage contributions. These contributions
are currently used in the software CINeMA (Confidence
in Network Meta-Analysis) to investigate the trustworthi-
ness of each comparison’s NMA estimate, based on the
risk of bias (and other features) of the individual studies
that contribute to the comparison [9, 19].
Another approach to percentage contributions was pub-
lished by Jackson and others [7] and also used elsewhere
[8, 20]. They suggest decomposing the total variance
matrix of parameter estimates from the meta-analysis
via a decomposition of the observed Fisher informa-
tion matrix into independent study-specific contribu-
tions, which sum up to the total variance matrix. Their
diagonal elements can be used to derive percentage study
weights for each parameter. They reveal how the variance
of a parameter is changed by the inclusion of a particular
study, assuming that all variance estimates (within- and
between-study variances) are fixed at the same value as in
the full analysis of all studies. Although this approach is
adequate when within-study information is pooled across
studies, the study-specific contributions can become dis-
torted in situations where across-study information con-
tributes to the parameter estimates, as in a network
meta-analysis [9].
In the present paper we suggest an approach that does
not require that the contributions to each network esti-
mate sum to 100%. The structure of the article is as fol-
lows. In the “Methods” we introduce our notation and give
the definition of the statistical importance of a study to a
network meta-analysis estimate. We then show that this is
a generalization of both the weights in a pairwise meta-
analysis and the direct and indirect evidence proportions
in a NMA. We give several interpretations of the quantity
‘direct evidence proportion’ and show that starting from
different interpretations of this quantity leads to different
generalizations. In the next section we present two real
data sets for illustrating our method. In the “Results” we
illustrate our concept by first applying it to simple special
cases and standard networks like pairwise MA, a chain of
treatments, and a circle, and then apply it to the two real
data examples.We discuss strengths and limitations of our
approach in the “Discussion”, and the paper ends with a
recommendation in the “Conclusion” sections.
Methods
We start with defining the importance of a study for any
network comparison in the framework of the common
effect model (traditionally termed ‘fixed effect model’).
We then show how our measure of importance is related
to the proportions of direct and indirect evidence for a
NMA estimate and give various interpretations for that.
We also extend it to the random effects model. While
the common effect model assumes that, for each com-
parison, all studies in the network are estimating the
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same (comparison-specific) true effect, the random effects
model assumes that the underlying effects of each com-
parison follow a distribution. Often a normal distribution
is assumed [21].
The importance of each study: variance reduction by
adding direct information
Consider a network meta-analysis. First concentrating on
the common effect model, we ask for the amount by which
the variance of an estimate from only indirect evidence is
reduced if direct information is added, or the relative loss
in precision when direct evidence is removed. There is no
reason to assume that these quantities add up to 100%.We
will come back to this point later.
The importance of each study for each NMA estimate is
defined as follows:
Conduct a NMA for the given network, called NMAall,
and then repeat the following steps for each study i in turn:
1 Remove study i from the network.
2 Conduct a NMA for the network without study i. Let
us denote this result by NMA−i. Accordingly, denote
the variance of any treatment effect estimate c by
Vall(c) if estimation is based on NMAall and by
V−i(c) if estimation is based on NMA−i .
3 For all comparisons c, define the importance of study
i for comparison c as
p(i, c) = 1 − Vall(c)V−i(c) =
V−i(c) − Vall(c)
V−i(c)
, (1)
thus giving the reduction of the variance of
comparison c with respect to the reduced network, if
the removed study is reinstalled.
The first step (removing study i from the network) could
lead to a disconnected network, rendering the calcula-
tion of V−i(c) impossible. For implementation in practice,
instead of removing study i, we set the standard errors
for all comparisons from study i to a very large value(e.g.,
10000), thus downweighting study i to practically zero.
This approach, known as ‘data augmentation’, goes back
to White and others [22] and was also used by Riley and
others [8]. While the interpretation of the difference of
the variances (numerator of (1)) depends on the partic-
ular scale, the proposed measure is dimensionless. We
have 0 ≤ p(i, c) ≤ 1 for all studies i and comparisons
c. We emphasize, however, that it makes no sense to add
up these importances across all studies, as they do not
sum up to 100% (in fact, the sum is often larger). We
do not call them (percentage) contributions. Rather, they
measure the importance of a study for a comparison.
The idea can be illustrated by comparing a network of
studies to a network of roads in a town. We consider
the traffic from some place A (a node in the network)
to another place B. The precision (or the weight) can be
interpreted as the transport capacity of the road network
between A and B, comparable to the conductance in an
electrical network [23]. If a particular road is closed due to
construction works, a traffic accident, or flooding, many
capacities decrease because some people have to make a
detour to go from A to B and thus add to the traffic on
other roads. The importance of this road for the way from
A to B is given by the relative reduction of the capacity of
the network due to the road closure.
The algorithm to calculate importances is implemented
in R function netimpact() in the R package netmeta
[24, 25], with a data set about Parkinson’s disease as exam-
ple. R code for all examples can be found in Additional File
1, with the resulting plots shown in Additional File 2.
The importance of a comparison for itself: direct and
indirect evidence proportions
In this paragraph, we show how our definition of impor-
tance was motivated by (but is not limited to) the known
concepts of direct and indirect evidence proportions in
the context of two-stage meta-analysis with inverse vari-
ance weights, still based on the common effect model.
We denote the variance estimates of the NMA effect
estimate, the direct effect estimate and the indirect effect
estimate of a comparison c by Vnma(c),Vdir(c),Vind(c)
and the inverse variance weights by wnma(c) =
[Vnma(c)]−1 , . . . and so on. These weights are quantities
that must be estimated from the data. Direct and indirect
paths and thus effects can be assumed as independent.
For readability, we omit hats on the symbols. The rules of
variance calculation lead to
Vnma(c) =
( 1
Vdir(c)
+ 1Vind(c)
)−1
= Vdir(c) · Vind(c)Vdir(c) + Vind(c)
(2)
[10, 11] and we may write
Vnma(c)
Vind(c)
= Vdir(c) − Vnma(c)Vdir(c) = 1 −
Vnma(c)
Vdir(c)
(3)
Vnma(c)
Vdir(c)
= 1 − Vnma(c)Vind(c) =
Vind(c) − Vnma(c)
Vind(c)
(4)
and in terms of inverse variance weights
Vnma(c)
Vdir(c)
= 1 − wind(c)wnma(c) =
wnma(c) − wind(c)
wnma(c)
. (5)
The direct evidence proportion of comparison c can be
defined via the inverse variance weights as
p(c) := wdir(c)wdir(c) + wind(c) =
Vind(c)
Vdir(c) + Vind(c) . (6)
Inserting (2) into (6) and using also (3) and (4), we obtain
for the proportions of direct and indirect evidence
p(c) = Vnma(c)Vdir(c) ; 1 − p(c) =
Vnma(c)
Vind(c)
. (7)
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In practice, users of the R package netmeta obtain
the values of p(c) via function netmeasures() [24].
We now show that different interpretations for p(c) are
possible and that these lead to different concepts of gen-
eralization.
Interpretation 1: proportion of direct evidence
The first interpretation of p(c), an immediate conse-
quence of the definition (6), is that it describes the pro-
portion of network precision for comparison c attributed
to direct evidence (from pairwise MA), in short, the con-
tribution of direct evidence to the network estimate c.
Accordingly, 1 − p(c) represents the contribution of indi-
rect evidence to this estimate.
Interpretation 2: reduction of the variance of a direct
comparison by adding indirect information
Equation (7) provides another interpretation: p(c) is the
proportion to which the variance of a pairwise MA is
shrunk when indirect evidence from the whole network is
added to the direct evidence, or, in other words, when all
network information is used.
Interpretation 3: relative reduction of the variance of a
comparison based solely on indirect evidence when adding
direct information
This interpretation is suggested by equation (4): p(c)
is the relative reduction of the variance of a compari-
son with only indirect evidence when information from
the direct comparison is added. Similarly, p(c) could
be interpreted as the loss in precision of a compari-
son when removing direct evidence (i.e., using exclusively
indirect evidence). This interpretation is motivated by
equation (5).
Whatever interpretation is preferred, high values mean
a high importance of the direct comparison for itself, and
low values mean low importance. The concept of ‘direct
evidence proportion’ quantifies the contribution of the
direct evidence from a comparison to its own NMA esti-
mate. Our definition (1) generalizes this to the importance
of a comparison/a study for the NMA estimate of any
(other) comparison.
Extension to the random effects model
So far, we used the common effect model to derive the
importances. The estimate τˆ 2 of the variance of the ran-
dom effects did not enter the calculations. Leaving out a
study from the data is expected to change τˆ 2. Particularly,
the variancemay decrease if the omitted study contributed
a lot to the between-study heterogeneity or inconsistency,
resulting in a negative importance for this comparison.
A possible workaround is to insert the estimate τˆ 2 from
the original network as a common heterogeneity variance
estimate for all subnetworks [7]. For pairwise MA, this
leads to the usual random effects weights, as we will see in
the next subsection.
Pairwise meta-analysis
We consider a pairwise MA with inverse variance weight-
ing, such that the (unstandardized) weight of study i is
given by wi = 1/Vi where Vi is the (estimated) vari-
ance of study i. The variance of the pooled common effect
estimate is then estimated by 1/
∑
j wj. Removing study i
from the MA gives another pooled estimate with variance
1/
∑
j =i wj. Equation (5) provides the importance of study
i for the pooled estimate
∑
j wj −
∑
j =i wj∑
j wj
= wi∑
j wj
which is the relative weight of study i in line with what
we would expect. For the random effects model, we use
an estimate of the heterogeneity variance τˆ 2 for the full
pairwise MA, and then remove one study in turn while
fixing the heterogeneity variance to this value. The same
argumentation as above shows that the procedure leads to
the usual random effects weights, w∗i = 1/
(
Vi + τˆ 2
)
and
corresponding relative weights.
This equality of weights is exact only if inverse vari-
ance weighting is used (e.g., for mean differences or Peto
odds ratios) and strictly only if these variances are known
(which is not true in practice), but not in general. For
example, due to the different weighting method, it does
not hold exactly for binary outcomes when using the
Mantel-Haenszel method.
One-stage network meta-analysis
Of note, however, the importance concept allows approx-
imate ‘study weights’ to be derived also for one-stage pair-
wise meta-analyses based on a generalized linear model,
such as logistic regression, where study weights are not
commonly provided. Importances can also be derived
from a one-stage approach based on the Mantel-Haenszel
method for NMA [26]. We provide an example in Addi-
tional File 1.
This allows deriving not only study weights, but also
direct and indirect evidence proportions for one-stage
NMA. For a comparison c, consider the network meta-
analysis of all studies except those that include c, and let
V−c(c) be the variance of the NMA effect estimate of c for
this reduced network. In analogy to (1), we may define the
direct evidence proportion of comparison c as
p(c, c) = 1 − Vall(c)V−c(c) =
V−c(c) − Vall(c)
V−c(c)
and the indirect evidence proportion as 1 − p(c, c) =
Vall(c)/V−c(c). We suggest also removing multi-arm stud-
ies that include c, following the ‘separate indirect from
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Table 1 Parkinson’s data. mean = mean lost worktime reduction, sd = standard deviation, n = sample size
Arm 1 Arm 2 Arm 3
Study Treatment mean sd n Treatment mean sd n Treatment mean sd n
1 placebo -1.22 3.70 54 ropinirole -1.53 4.28 95
2 placebo -0.70 3.70 172 pramipexole -2.40 3.40 173
3 placebo -0.30 4.40 76 pramipexole -2.60 4.30 71 bromocriptine -1.2 4.3 81
4 ropinirole -0.24 3.00 128 bromocriptine -0.59 3.00 72
5 ropinirole -0.73 3.00 80 bromocriptine -0.18 3.00 46
6 bromocriptine -2.20 2.31 137 cabergoline -2.50 2.18 131
7 bromocriptine -1.80 2.48 154 cabergoline -2.10 2.99 143
direct design evidence’ (SIDDE) approach suggested by
Efthimiou et al. [26].
Data sets
Parkinson’s data
This network consists of seven studies comparing five
treatments: placebo, coded 1, and four active drugs,
pramipexole (coded 2), ropinirole (3), bromocriptine (4),
and cabergoline (5) [27]. The outcome is the mean lost
work-time reduction in patients given dopamine agonists
as adjunct therapy in Parkinson’s disease, given as sample
size, mean and standard deviation in each trial arm. The
data, shown in Table 1, is used as an example in the supple-
mentary material of [28] and available from the R package
netmeta [24], see the R code in Additional file 1.
Thrombolytic data
This data set, originally published by Boland and others
[29], was extended and presented by Lu and Ades [30] and
successively analyzed by many others. We took the data
from Riley and others [8]. The outcome is mortality at 30-
35 days. This network consists of 28 studies (13 designs,
i.e., different combinations of treatments in a study) of 8
treatments after acute myocardial infarction. We follow
Riley and others [8] denoting these treatments by A =
streptokinase, B = accelerated alteplase, C = alteplase, D =
streptokinase + alteplase, E = tenecteplase, F = reteplase,
G = urokinase, and H = anistreptilase. Figure 1 shows
the network graph for the thrombolytic data which are
provided in Additional File 3.
Results
We first apply our method to a number of hypotheti-
cal examples that nevertheless lead to insight into the
interpretation of our new measure of importance.
Hypothetical networks
A chain of n − 1 studies connecting n treatments
Suppose we have three studies comparing A to B, B
to C, and C to D with variances V1,V2,V3. We look
at comparison A:D. The direct evidence proportion for
comparison A:D is 0, the indirect evidence proportion is
1. The variance of the NMA (i.e., the indirect) estimate
for comparison A:D is Vall(A:D) = V1 + V2 + V3. If
one of the studies, regardless which, is omitted, the vari-
ance becomes infinite, and the importance of this study
for comparison A:D becomes 1. The interpretation is that
this study (like the others) is of maximum importance for
the comparison, which is indeed true. For the approach
by Papakonstantinou and others, henceforth called contri-
butions approach, each study would contribute 1/3 to the
estimate of comparison A:D [9].
Fig. 1 Network graph of thrombolytic data. The gray shaded areas
indicate two three-arm studies: study 1 (lightgray, A-B-D), and study 2
(darkgray, A-C-H). A = streptokinase, B = accelerated alteplase, C =
alteplase, D = streptokinase + alteplase, E = tenecteplase, F =
reteplase, G = urokinase, H = anistreptilase
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Fig. 2 Left panel: A circle of n treatments with equal variances. Right panel: A network with a bridge
A circle of n treatments with equal variances
Suppose we have a closed circular network of n treatments
connected by exactly n two-arm studies, each comparing
two treatments in turn like in Fig. 2 (left, here n = 7) and
each having variance 1.
We consider an arbitrary comparison c = t1 : t2 of treat-
ments t1 and t2 (t1 = t2) in the network such that the
distance (the number of steps) from t1 to t2 is 1 ≤ l ≤ n/2.
The NMA variance of comparison c is
Vall(c) = 11
l + 1n−l
= l(n − l)n .
For example, comparison A:D (distance 3) has the NMA
variance 3*4/7. If a study is removed from the network,
evidence for comparison c can only go one way. If, for
example, the study connecting B and C is removed from
the network, the variance for comparison A:D becomes
4, because the shorter connection via B and C is broken.
In general, if the removed study lies on the shorter path
from t1 to t2 (length l), the variance becomes n − l, if
the removed study lies on the longer path, the variance
becomes l. Thus the importance of each study i on the
shorter path for comparison c is
p(i, c) = 1− Vall(c)V−i(c) = 1−
l(n − l)
n(n − l) = 1−
l
n =
n − l
n
and the importance of each study j on the longer path for
comparison c is
p(j, c) = 1− Vall(c)V−j(c) = 1−
l(n − l)
nl = 1−
n − l
n =
l
n .
Thus, plausibly, each of the l studies on the shorter path
has greater importance for the comparison than the n − l
studies on the longer path, as we have presumed l ≤ n− l.
For the example, the importance of study B:C for compar-
ison A:D is (7 - 3)/7 = 4/7. Particularly, it follows that the
direct evidence proportion for each pair that is directly
compared (i.e., adjacent, l = 1) is (n−1)/n and the indirect
evidence proportion is 1/n, while for all other pairs the
direct evidence proportion is 0 and the indirect evidence
proportion is 1. By contrast, the contributions approach
would attribute a contribution of n−lnl to each piece on the
shorter path and ln(n−l) to each piece on the longer path,
such that the sum of all contributions is 1.
A network with a bridge
We consider the network given on the right-hand panel of
Fig. 2 with seven studies, all again having variance 1. We
call comparison C:D a bridge [9, Supplementary file 3].
Table 2 gives the importances of each study for all com-
parisons. Study CD has importance 1 for all comparisons
between the two parts of the network (A:D, A:E, A:F, B:D,
Table 2 Importances of each study for the network with a bridge. For sake of transparency, the symbol − represents zero
Comparisons
Study A:B A:C B:C C:D D:E D:F E:F A:D B:D C:E C:F A:E A:F B:E B:F
AB 0.67 0.33 0.33 – – – – 0.17 0.17 – – 0.12 0.12 0.12 0.12
AC 0.33 0.67 0.33 – – – – 0.44 0.17 – – 0.36 0.36 0.12 0.12
BC 0.33 0.33 0.67 – – – – 0.17 0.44 – – 0.12 0.12 0.36 0.36
CD – – – 1 – – – 1 1 1 1 1 1 1 1
DE – – – – 0.67 0.33 0.33 – – 0.44 0.17 0.36 0.12 0.36 0.12
DF – – – – 0.33 0.67 0.33 – – 0.17 0.44 0.12 0.36 0.12 0.36
EF – – – – 0.33 0.33 0.67 – – 0.17 0.17 0.12 0.12 0.12 0.12
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B:E, B:F, C:D, C:E, C:F) and importance 0 for all compar-
isons within the same part of the network (A:B, A:C, B:C,
D:E, D:F, E:F). Studies AB, AC and BC have no impor-
tance for comparisons outside the triangle ABC (C:D, C:E,
C:F, D:E, D:F, E:F), and vice versa for triangle DEF. The
table also shows that the direct evidence proportion for
comparisons A:B, A:C, B:C, D:E, D:F, and E:F is 2/3, and
the direct evidence proportion for comparison C:D (the
bridge) is 1.
To compare this with the contributions approach [9],
Table 3 shows the contributions of each study to a com-
parison in the bridge network. For all comparisons of
treatments from different parts of the network the values
of contributions differ from those of importances. This
is because the contributions approach attributes lower
weights to a study when the network distance between the
treatments is greater.
A generic triangle
Consider a NMA with three treatments A, B and C and
three studies comparing A to B, A to C, and B to C with
variancesVAB,VAC ,VBC . We focus on comparison A:B. Its
direct estimate has variance VAB and its NMA estimate
has variance
Vall(A : B)= 1V−1AB + (VAC + VBC)−1
= VAB (VAC + VBC)VAB + VAC + VBC
The direct evidence proportion for A:B is
VAC + VBC
VAB + VAC + VBC .
If one of the studies on the indirect pathway from A to
B (say AC) is removed, only direct evidence remains, and
we get its importance for comparison A:B as
p(AC,A : B) = 1 − Vall(A : B)VAB = 1 −
VAC + VBC
VAB + VAC + VBC
= VABVAB + VAC + VBC ,
(8)
the same if BC is removed. In other words, it does not
matter whether we remove AC or BC or which of them
has smaller variance, the importance of the two studies is
equal and also equal to the indirect evidence proportion.
The indirect evidence proportion comes from the com-
bination of studies AC and BC and depends on the sum
of their variances. This example shows that it does not
make sense to add up the importances of all studies. It also
challenges the idea of breaking up the indirect evidence
proportion into additive parts from each study.
Real data networks
We now apply our method to the two real data sets
presented before.
Parkinson’s data
Figure 3 shows the network graph of the Parkinson’s data
[28] (top left panel) and, for each of the seven studies, the
effect of removing a single study (study 1: comparison 1:3;
study 2: comparison 1:2; study 3: comparisons 1:2, 1:4, 2:4;
studies 4,5: comparison 3:4; studies 6,7: comparison 4:5).
The resulting importances from the common effect
model are given in Table 4. The last row of the table
provides the direct evidence proportions for each compar-
ison.
We see that, not surprisingly, the most important study
is the three-arm study 3. It is important not only for
comparisons 1:2, 1:4 and 2:4, but also for comparison 1:3
and the indirect comparisons 1:5, 2:3 and 2:5. However,
for comparison 1:2, study 2 is even more important, and
for comparison 1:3 study 1 is more important. Study 4
(comparison 3:4) is the most important study for both
comparisons 3:4 and 3:5, whereas the less precise study
5 (likewise comparing 3:4) is less important for all com-
parisons. For comparison 4:5, only studies 6 and 7 are
important. Study 6 is uniformly more important than
study 7 (both comparing 4:5).
Study 1, though not very precise, is surprisingly impor-
tant for comparison 1:4. The only direct evidence for
comparison 1:4 comes from the three-arm study 3 with
Table 3 Contributions of each study for the network with a bridge following the contributions approach [9]
Comparisons
Study A:B A:C B:C C:D D:E D:F E:F A:D B:D C:E C:F A:E A:F B:E B:F
AB 0.67 0.33 0.33 – – – – 0.11 0.11 – – 0.07 0.07 0.07 0.07
AC 0.33 0.67 0.33 – – – – 0.33 0.11 – – 0.22 0.22 0.07 0.07
BC 0.33 0.33 0.67 – – – – 0.11 0.33 – – 0.07 0.07 0.22 0.22
CD – – – 1 – – – 0.44 0.44 0.44 0.44 0.29 0.29 0.29 0.29
DE – – – – 0.67 0.33 0.33 – – 0.33 0.11 0.22 0.07 0.22 0.07
DF – – – – 0.33 0.67 0.33 – – 0.11 0.33 0.07 0.22 0.07 0.22
EF – – – – 0.33 0.33 0.67 – – 0.11 0.11 0.07 0.07 0.07 0.07
Entries in italics differ from those in Table 2
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Fig. 3 Parkinson’s data (top left panel) with each study removed in turn (other panels). 1 = placebo, 2 = pramipexole, 3 = ropinirole, 4 =
bromocriptine, 5 = cabergoline
relatively small precision. The only other path from treat-
ment 1 to treatment 4 goes via treatment 3: study 1
provides comparison 1:3, and studies 4 and 5 both provide
comparison 3:4. If study 1 is deleted, this path (1 → 3 →
4) breaks down, whereas if either study 4 or 5 is deleted,
the other study (4 or 5) remains, and the path still exists.
Thus study 1 is more important for comparison 1:4 than
studies 4 and 5.
For each direct comparison, we may compare this to the
contributions (weights) of each study in a pairwise meta-
analysis, given in Table 5. For comparisons solely informed
by direct evidence (here comparison 4:5) they agree with
the corresponding importances.
Thrombolytic data
Table 6 shows results of our method (random effects
model) when applied to the thrombolytic data [8, Tables
3 and 4]. The importance values are not directly compa-
rable to percentage contributions, as they do not add up
to 100%. Therefore we find major differences to the per-
centage contributions given by Riley and others [8]. In all
these cases, the importance (as we measure it) exceeds the
percentage contribution (as defined in [8]). Particularly,
study 17 is the only one including treatment E (it com-
pares B to E), and if it is omitted, E is no more part of
the network. Therefore study 17 has maximal importance
for comparison A:E, compared to 67.13% contribution fol-
lowing Riley’s method. The three-arm study 1 (A:B:D) is
more important for comparisons A:E and A:F than when
measured by Riley et al.’s % contribution approach. Also
study 18, comparing B:F, has higher importance for com-
parisons A:B, A:E and A:F than when measured by Riley
et al.’s % contribution approach. Again, the importance
values may be compared to the study weights in pairwise
Table 4 Importance of each study for the comparisons in the Parkinson’s data
Comparisons
Study Design 1:2 1:3 1:4 1:5 2:3 2:4 2:5 3:4 3:5 4:5
1 1:3 0.029 0.531 0.405 0.364 0.418 0.294 0.264 0.126 0.092 –
2 1:2 0.756 0.076 0.121 0.104 0.402 0.379 0.345 0.013 0.009 –
3 1:2:4 0.244 0.469 0.595 0.553 0.503 0.617 0.582 0.126 0.092 –
4 3:4 0.005 0.128 0.101 0.086 0.130 0.064 0.056 0.535 0.449 –
5 3:4 0.002 0.061 0.048 0.041 0.062 0.030 0.026 0.339 0.266 –
6 4:5 – – – 0.178 – – 0.157 – 0.285 0.577
7 4:5 – – – 0.105 – – 0.092 – 0.177 0.423
Direct evidence (%) 97.1 53.1 47.4 0.0 0.0 55.8 0.0 87.4 0.0 1.0
Direct evidence is printed in bold. The last row shows the proportion of direct evidence for each comparison. 1 = placebo, 2 = pramipexole, 3 = ropinirole, 4 = bromocriptine,
5 = cabergoline
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Table 5 Study weights for pairwise meta-analysis of
comparisons in the Parkinson’s data (common effects model)
Comparison Study Design Weight
1:2 2 1:2 0.779
3 1:2:4 0.221
3:4 4 3:4 0.612
5 3:4 0.388
4:5 6 4:5 0.577
7 4:5 0.423
1 = placebo, 2 = pramipexole, 3 = ropinirole, 4 = bromocriptine, 5 = cabergoline
meta-analyses, given in Table 7 for the random effects
model.
A visualization as a heatmap is shown in Fig. 4. Dark
colors mean that a study (in the column) is important
for the comparison in the row. It is not surprising that
studies 1 and 2, both three-arm studies with over 40.000
patients each, are at the top level of importance for most,
but not all comparisons. As mentioned before, study 17
(B:E) is important for all comparisons with E, study 18
(B:F) for all comparisons with F, and study 21 (B:G) for all
comparisons with G.
Discussion
In two-stage pairwise MA, the pooled effect estimate is
a weighted mean of the study-specific estimates. Rela-
tive study weights (for example inverse variance weights)
can be defined and interpreted as proportions or percent-
ages, adding to 100%. Notably, inverse variance weights
are treated as if they were fixed, though they are estimates
of random variables, which has been criticized [31]. Most
existing approaches to generalize the concept of ‘weights’
to NMA aim to define study contributions that can be rep-
resented as proportions or percentages, like in pairwise
MA. At least, it is possible to quantify the proportion of
direct and indirect evidence for each NMA estimate, as
outlined in the “Methods” section.
Papakonstantinou and others showed that entries in a
hat matrix row can be interpreted as a flow through the
network where different signs indicate the direction of the
flow [9]. Consequently, it makes little sense to add the val-
ues of the entries of the hat matrix, as the direction is
embedded. In the analogy of a flood, it is always the same
water we see in all these coefficients.
Other possible generalizations of the direct evidence
proportion
The idea of comparing variances also underlies the ‘Bor-
rowing of strength’ (BoS) measure, developed in the more
general framework of multivariate meta-analysis [7, 8].
With respect to interpretation, Copas and others distin-
guish between ‘Direct interpretation’ (which corresponds
to our interpretation 1), ‘Add-one-in interpretation’ and
‘Leave-one-out interpretation’ (which both refer to our
interpretation 3) [20].
Different interpretations suggest different ideas of gen-
eralizing the p(c). A generalization of interpretation 1
(i.e., splitting direct and indirect contributions) aims to
determine the contribution of each comparison (or, alter-
natively, of each study) to a given NMA estimate, such
that these contributions add up to 100% (‘percentage con-
tributions’). This means splitting 1 − p(c), the proportion
of indirect evidence, further into parts coming from dif-
ferent comparisons or studies, as done by [9]. Starting
from interpretation 2 would mean looking for a quantity
that describes the proportion to which the variance of a
given direct estimate at hand decreases by adding indirect
evidence from a particular other study. However, adding
another comparison to a given direct comparison makes
only sense if the enlarged network is connected, that is if
the new study and the comparison in question have treat-
ments in common or if further studies are added. Thus,
interpretation 2 does not seem to be a good starting point
for generalization. Therefore, we focus on a generalization
that is motivated by interpretation 3.
The concept of importance for the variance
Our concept of study importance does not start from the
hat matrix, but interprets the importance of a study to a
comparison as the relative reduction of the variance of the
estimate when adding the study to the network.We refrain
from requesting the values to sum up to 1. For exam-
ple, a study can be essential for a comparison (like study
17 in the thrombolytic data for all comparisons involv-
ing treatment E), thus providing an importance of 1, but
other studies may be also (or even equally) important. For
instance, in the chain or the circle example, all studies on
a path are equally important for the comparison of the
path’s ends.
Versatility of the importance approach
We emphasize that our definition does not rely on, and
actually is not restricted to, inverse variances. This is
because no variance estimate of a direct comparison
enters definition (1). Rather, we define importances as
ratios of estimated variances from two different NMAs
which could be based on any method, including one-stage
approaches or specific methods for binary outcomes.
In Additional File 1, we show how to use the Mantel-
Haenszel (MH) method to estimate importances both in a
pairwise meta-analysis and a network meta-analysis using
the recently developed MH method for NMA [26]. This
works also in a Bayesian framework.
Importance and contribution
For pairwise MA there is no ambiguity: the contribu-
tions (weights) of all studies add to 1, however they were
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Table 6 Importance of each study for the comparisons to treatment A for the thrombolytic data, multiplied by 100 for comparison to
[8, Table 4]
Comparisons
Study Design A:B A:C A:D A:E A:F A:G A:H
1 ABD 82.10 0.03 99.50 59.69 50.56 2.68 0.06
2 ACH 0.30 59.39 0.03 0.10 0.07 0.50 96.81
3 AC 0.00 0.31 0.00 0.00 0.00 0.00 0.05
4 AC 0.00 0.13 0.00 0.00 0.00 0.00 0.02
5 AC 0.00 0.13 0.00 0.00 0.00 0.00 0.02
6 AC 0.00 38.20 0.00 0.00 0.00 0.21 9.20
7 AC 0.00 0.22 0.00 0.00 0.00 0.00 0.04
8 AC 0.00 0.38 0.00 0.00 0.00 0.00 0.06
9 AC 0.00 0.29 0.00 0.00 0.00 0.00 0.05
10 AD 0.04 0.00 0.50 0.01 0.01 0.00 0.00
11 AF 15.78 0.00 1.57 5.70 45.67 0.11 0.00
12 AG 0.14 0.08 0.01 0.05 0.03 19.35 0.01
13 AH 0.00 0.03 0.00 0.00 0.00 0.00 0.15
14 AH 0.00 0.04 0.00 0.00 0.00 0.00 0.26
15 AH 0.00 0.03 0.00 0.00 0.00 0.00 0.16
16 AH 0.00 0.12 0.00 0.00 0.00 0.00 0.75
17 BE 0.00 0.00 0.00 100.00 0.00 0.00 0.00
18 BF 14.98 0.00 1.47 5.38 52.79 0.11 0.00
19 BF 0.11 0.00 0.01 0.03 0.67 0.00 0.00
20 BG 0.11 0.02 0.01 0.04 0.02 6.75 0.00
21 BG 0.70 0.15 0.06 0.23 0.16 31.50 0.02
22 BH 0.71 0.08 0.06 0.23 0.16 0.00 0.49
23 BH 0.45 0.05 0.04 0.15 0.10 0.00 0.31
24 CG 0.08 0.09 0.01 0.03 0.02 12.11 0.01
25 CG 0.12 0.13 0.01 0.04 0.03 17.31 0.02
26 CG 0.09 0.09 0.01 0.03 0.02 12.59 0.01
27 CH 0.00 0.13 0.00 0.00 0.00 0.00 0.32
28 CH 0.00 0.07 0.00 0.00 0.00 0.00 0.16
Direct evidence 0.82 0.99 0.98 0.00 0.46 0.19 0.89
Direct evidence is printed in bold. The last row shows the proportion of direct evidence for each comparison in a column. A = streptokinase, B = accelerated alteplase, C =
alteplase, D = streptokinase + alteplase, E = tenecteplase, F = reteplase, G = urokinase, H = anistreptilase
determined. Likewise, in NMA the direct evidence can be
broken down into percentage weights. The division into
direct and indirect contributions in NMA (which add to 1)
is also possible. However, it is the breakdown of percent-
age weights for the indirect evidence that does not work.
Therefore, for the more general situation, we use ‘impor-
tance’ instead of ‘contribution’, because these two words
have different connotations. Coming back to the example
of the chain, the importance of each of the studies con-
necting A to D is 1, meaning that each of these studies
is needed for comparing A to D. By contrast, the con-
cept of ‘contribution’ by Papakonstantinou and others [9]
accounts for the fact that though all these studies are nec-
essary, none of them alone is sufficient for comparing A
and D. Therefore for this example they divide 1 by the
number of linking studies, which is three, leading to a con-
tribution of 1/3 for each study in the path. However, this
approach is not strictly deterministic, as demonstrated in
[9, Supplementary File 3].
Combinations of studies matter
The importance of a study for a comparison must be
seen in combination with other studies. Possible exten-
sions could be to define the importance of combinations
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Table 7 Study weights for the thrombolytic data (random effects
model)
Comparison Study Design Weight (%)
A:C 2 ACH 59.93
3 AC 0.32
4 AC 0.13
5 AC 0.13
6 AC 38.59
7 AC 0.22
8 AC 0.39
9 AC 0.30
A:D 1 ABD 99.49
10 AD 0.51
A:H 2 ACH 98.52
13 AH 0.17
14 AH 0.29
15 AH 0.17
16 AH 0.85
B:F 18 BF 68.54
19 BF 31.46
B:G 20 BG 17.79
21 BG 82.21
B:H 22 BH 61.26
23 BH 38.74
C:G 24 CG 28.83
25 CG 41.19
26 CG 29.99
C:H 2 ACH 98.77
27 CH 0.81
28 CH 0.42
A = streptokinase, B = accelerated alteplase, C = alteplase, D = streptokinase +
alteplase, E = tenecteplase, F = reteplase, G = urokinase, H = anistreptilase
of studies, or the importance of a single patient in a
study to a NMA estimate. We emphasize that the impor-
tance of a study is always conditional on the other studies
being included in the network. There is an analogy to a
multivariable regression model: If the association of each
regressor (covariate) xi with the dependent variable is con-
sidered in isolation, the proportion of explained variance
of the dependent variable is given by its coefficient of
determination, r2i , which is bounded between 0 and 1.
When considering more than one covariate, it does not
make sense to consider their r2i values separately (or even
to add them). The proportion of explained variance for the
multivariable model depends on the selected variables and
their correlation structure. While the goodness of fit for
the model can be measured by its coefficient of determi-
nation, it is far less clear what is meant by (or how to mea-
sure) the ‘contribution of each variable to the outcome’, let
alone in percent. This is also true for the regression coeffi-
cients, as each of them depends on the selected model. In
our view, the situation in NMA is similar. Indeed, NMA
can be written as a meta-regression model, and so has the
same issues of defining the contribution of each variable
in isolation.
Random effects model
For the random effects model, the omission of a study may
decrease some variances, if τˆ 2 is not fixed. For example,
for a circular network (Fig. 2, left panel) leaving out a study
always leads to zero inconsistency, because the resulting
network is free of loops. If inconsistency is large for the
primary network, the variances of all estimates decrease
for the subnetworks, resulting in negative importances. In
principle, we could accept negative importances: an obvi-
ous interpretation would be that a study with negative
importance ‘disturbs’ the network. However, we prefer to
fix τˆ 2 to the heterogeneity variance estimate from the full
network, in line with the definition of the random effects
weights for pairwise MA. This means that for the random
effects model information of the full network enters the
estimation for all subnetworks. Moreover, as τˆ 2 does not
only depend on the variances, but also on the treatment
effect estimates of all studies, information on the treat-
ment effect estimates enters the importance values in the
random effects model (as do the random effects weights
in a pairwiseMA). This issue is covered in detail in [7] and
led Copas and others to focus mainly on common effect
models [20].
Impact on the variance or on the effect estimates?
The importance of a study in a network MA can be
considered from different aspects. In this article, we fol-
low [6, 8, 9], focussing on the impact of a study on the
variances. This type of approach generalizes the inverse
variance weights in pairwise common effectsMA and, like
these, ignores the impact of a study on the actual treat-
ment effect estimates. A study may be important because
of its high precision, but this does not necessarily impact
the size or direction of the effect estimates. For example,
there is a marked inconsistency between the direct and
the indirect estimates for comparison B:H in the throm-
bolytic data example: the direct effect for B:H deviates
from the indirect effect, which is mainly driven by the
large studies 1 and 2. Such deviations are not the focus
of variance-based methods. For those mainly interested
in treatment effects, we point to approaches to identify
influential studies (including ‘outliers’) which impact the
effect estimates [2–5]. These concepts do not rely exclu-
sively on the structure of the network and the variances
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Fig. 4 A grayscale heatmap of importances for thrombolytic data. Darker colors represent greater importance of a study (column) for a comparison
(row)
of the studies, but also account for their effect estimates
and the extent to which they are consistent with esti-
mates from other studies. These methods differ from the
variance-based methods in their aims.
Conclusion
We propose to measure the importance of a study for a
comparison in a NMA as the relative reduction of the
variance of the estimate when adding the study to the net-
work, or, equivalently, the relative loss of the precision
when the study is left out. This works with both two-
stage and one-stage NMA, also in a Bayesian framework.
For pairwise MA, importances reduce to the usual inverse
variance weights. Importances are values between 0 and
1 and cannot be expected to add up to 1. An importance
of 1 means that the study is an essential link of the path-
way in the network connecting one of the treatments with
the other. This may possibly also hold for multiple studies
on a pathway. The importance of a study for a comparison
depends on the network structure and on other studies
on the paths from one node in the network to another.
Accordingly, our variance-based measure provides some
insight into the network structure. For the common effect
model, importances, like the weights in pairwise MA, are
not informative with respect to the size, direction, or risk
of bias of the effect estimates. This is different for the ran-
dom effects model where the effect estimates influence
the importances via τˆ 2 like the random effect weights in
pairwise MA.
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